Most Frequent Side Effects of Humira
Humira (adalimumab), used for conditions like rheumatoid arthritis, psoriasis, and Crohn's disease, commonly causes injection site reactions in up to 20% of patients. These include redness, itching, pain, swelling, or bruising at the injection spot, typically mild and short-lived.[1][2]
Upper respiratory infections occur in about 17% of users, along with headaches (12%) and rash (6%). Sinusitis and nausea affect around 5-10%.[1][3]
Serious Risks Patients Report
Serious infections like tuberculosis or fungal infections arise in 4% of cases, often due to immune suppression. Increased risk of lymphoma or skin cancer is noted in post-marketing data.[2][4]
Heart failure worsening, lupus-like symptoms, and blood disorders (low white cells or platelets) are rarer but flagged in warnings.[1][3]
Side Effects by Condition Treated
In rheumatoid arthritis trials, serious infections hit 8%, versus 4% on placebo. Psoriasis users see more skin reactions; Crohn's patients report abdominal pain or diarrhea more often.[2][4]
| Condition | Common Side Effects (>5%) | Serious Risks |
|-----------|---------------------------|---------------|
| Rheumatoid Arthritis | Injection reactions, infections, headache | TB reactivation, malignancies |
| Psoriasis | Rash, upper respiratory infection | Skin cancer, hepatitis B flare |
| Crohn's Disease | Nausea, abdominal pain | Opportunistic infections[1][2] |
What Happens If Side Effects Worsen
Seek immediate care for persistent fever, cough, unexplained weight loss, or neurological changes like vision loss (possible demyelinating disorders). Most resolve after stopping treatment, but monitoring bloodwork is standard.[3][4]
Managing Common Side Effects
Rotate injection sites, use room-temperature Humira to reduce pain, and premedicate with antihistamines if reactions recur. Report infections early to avoid hospitalization.[2]
Sources
[1]: Humira Prescribing Information (FDA)
[2]: Drugs.com - Humira Side Effects
[3]: Mayo Clinic - Adalimumab
[4]: MedlinePlus - Adalimumab